Cytokinetics (CYTK) Form 4: Robert Blum reports 5,000-share sale

Rhea-AI Filing Summary

Insider transaction summary for CYTK: The Form 4 shows Robert I. Blum, President & CEO and a director of Cytokinetics Inc. (CYTK), reported a sale of 5,000 shares of the issuer's common stock on 08/15/2025 at a price of $38.42 per share. After the reported sale, Mr. Blum is recorded as directly owning 383,108 shares. The filing also discloses indirect holdings of 2,083 shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust.

The Form 4 was filed by one reporting person and indicates the transaction may have been made pursuant to a written plan under Rule 10b5-1. The filing is signed by an attorney-in-fact for Mr. Blum on 08/15/2025.

Insights

Financial Analyst

TL;DR: CEO/director sold a small block of shares; ownership remains substantial and the disclosure follows standard Section 16 reporting.

The 5,000-share disposition at $38.42 reduces the reporting person’s direct stake to 383,108 shares while two irrevocable trusts hold 2,083 shares each. The sale size relative to the reported direct holding appears limited. The filing notes a 10b5-1 plan checkbox, suggesting the transaction may have been pre-planned; however, the form does not provide plan details. This is a routine insider sale disclosure under Section 16.

Corporate Governance Expert

TL;DR: Disclosure is complete for the reported transaction; governance processes appear observed based on the form's content.

The Form 4 lists the reporting person’s roles (President & CEO and director) and provides direct and indirect ownership breakdowns plus an attorney-in-fact signature. The 10b5-1 indication is checked, which, if accurate, typically limits concerns about opportunistic trading, but the filing itself does not include the plan’s terms. No additional governance actions or departures are disclosed.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blum Robert I

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/15/2025		S		5,000	D	$38.42	383,108	D
Common Stock								2,083	I	by Trust 1(1)
Common Stock								2,083	I	by Trust 2(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares held by The Bridget Blum 2003 Irrevocable Trust.

2. Shares held by The Brittany Blum 2003 Irrevocable Trust.

	/s/ John O. Faurescu, attorney-in-fact for Mr. Blum	08/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CYTK CEO Robert Blum report on the Form 4?

Mr. Blum reported a sale of 5,000 shares of Cytokinetics common stock on 08/15/2025 at $38.42 per share.

How many CYTK shares does Robert Blum own after the reported sale?

The Form 4 reports 383,108 shares as directly owned by Mr. Blum following the transaction, plus two trusts holding 2,083 shares each indirectly.

Was the Form 4 transaction indicated as under a 10b5-1 plan for CYTK?

Yes. The filing has the checkbox marked indicating the transaction was made pursuant to a written plan intended to satisfy Rule 10b5-1(c).

Who signed the Form 4 for Robert Blum?

The Form 4 is signed by John O. Faurescu, attorney-in-fact for Mr. Blum with the signature date 08/15/2025.

Does the Form 4 disclose Mr. Blum’s roles at Cytokinetics (CYTK)?

Yes. The filing lists Mr. Blum as both a Director and an Officer with the title President & CEO.